Anthera Pharmaceuticals Stock Return On Equity
| ANTHDelisted Stock | USD 0.0001 0.00 0.00% |
Anthera Pharmaceuticals fundamentals help investors to digest information that contributes to Anthera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Anthera Pink Sheet. The fundamental analysis module provides a way to measure Anthera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anthera Pharmaceuticals pink sheet.
Anthera |
Anthera Pharmaceuticals Company Return On Equity Analysis
Anthera Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Anthera Pharmaceuticals Return On Equity | -5.69 |
Most of Anthera Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anthera Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Anthera Pharmaceuticals has a Return On Equity of -5.6885. This is 76.27% lower than that of the Biotechnology sector and 84.4% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Anthera Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anthera Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Anthera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Anthera Pharmaceuticals by comparing valuation metrics of similar companies.Anthera Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Anthera Fundamentals
| Return On Equity | -5.69 | ||||
| Return On Asset | -1.42 | ||||
| Current Valuation | (7.47 M) | ||||
| Shares Outstanding | 26.18 M | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | (0.20) X | ||||
| Price To Book | 0.11 X | ||||
| Gross Profit | (28.49 M) | ||||
| EBITDA | (26.59 M) | ||||
| Net Income | (26.87 M) | ||||
| Cash And Equivalents | 8.09 M | ||||
| Cash Per Share | 0.31 X | ||||
| Debt To Equity | 1.61 % | ||||
| Current Ratio | 3.30 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (36.9 M) | ||||
| Short Ratio | 2.09 X | ||||
| Earnings Per Share | (1.76) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | -108.04 | ||||
| Market Capitalization | 617.83 K | ||||
| Total Asset | 3.67 M | ||||
| Retained Earnings | (436.8 M) | ||||
| Working Capital | 39.39 M | ||||
| Current Asset | 47.86 M | ||||
| Current Liabilities | 8.47 M | ||||
| Net Asset | 3.67 M |
About Anthera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anthera Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anthera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anthera Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Anthera Pink Sheet
If you are still planning to invest in Anthera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anthera Pharmaceuticals' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |